Osivax

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, universal influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications...

Biotechnology,immunology,antigens,vaccine,influenza,universal,cellular immune response,cd8 t-cell,infectious diseases,immuno-oncology,and covid

Osivax operates in the Biotechnology research industry.

Osivax's revenue is 11m - 100m

Osivax has 51 - 200 employees.